ASM was awarded funding from CDC to develop deliver accredited training to educate the clinical microbiology workforce on NGS technology. Trainings will begin in early 2023.
ASM Applauds Funding for New Pathogen Genomics Centers
The CDC has announced that $90 million in funding from the American Rescue Plan will support the Pathogen Genomics Centers of Excellence.
Academy Report
This 2016 Academy report provides suggestions for combating current limitations of NGS-based diagnostic tests in clinical settings.
What is Next-Gen Sequencing and AMD?
DNA sequencing establishes the order of the bases that make up the genetic code of an organism. Next-generation DNA sequencing (NGS) refers to the use of technologies for sequencing DNA that became available shortly after the completion of the Human Genome Project. The CDC's AMD program harnesses the power of next-generation genomic sequencing, high-performance computing and epidemiology to study pathogens.
ASM' Advocates for Next-Gen Sequencing
Working With Congress
Supporting Legislation:
- ASM Leads Support Letter for House Tracking Pathogens Act.
- ASM Praises Inclusion of Tracking Pathogens Act in Draft Legislation.
- ASM and Stakeholders Endorse Tracking COVID-19 Variants Act.
- ASM Leads Support Letter for CDC AMD Program Funding.
- ASM Leads Joint Letter Supporting Advanced Molecular Detection Program Funding.
- ASM Leads Joint Letter Supporting CDC Advanced Molecular Detection Program.
- ASM Honors Senator Baldwin and Representative Bera for Leadership and Advocacy.
- ASM Leads Support Letter for CDC Advanced Molecular Detection Program Funding.
- ASM Urges Congress to Invest $40 Million in CDC AMD Program.
- ASM and Partners Request $60M for AMD Program at CDC
Working with CDC
Previous Updates
With $1.7 billion in multi-year funding from the American Rescue Plan Act of 2021, the AMD program is supporting state, local and territorial public health laboratories with more staff and resources to collect specimens for COVID-19 testing, sequence them to identify and track SARS-CoV-2 variants and share data. In addition to the current investments in state and local jurisdictions included in the data below, CDC has been supporting national SARS-CoV-2 sequencing capacity through contracts with large commercial diagnostic laboratories, which have received over $240 million to sequence specimens from across the °®¶¹´«Ã½ States.
Why Invest in Genomic Sequencing?
Significantly boosting U.S. genetic surveillance and viral sequencing is key to moving beyond the current COVID-19 pandemic and effectively responding to future challenges, not only associated with novel and evolving infectious diseases, but also seasonal threats, antimicrobial resistance and food borne pathogens.
Estimates of SARS-CoV-2 Variant Prevalence in the U.S.
.
Hear From Experts
Podcasts
Dr. Joe DeRisi talks about how genomics helped solve the mystery of dying leopard sharks in San Francisco bay, how a “virochip” array helped identify the SARS virus, how genomics can help identify unknown causes of encephalitis, how the sewer may hold the key to predicting infectious disease outbreaks and how computational capabilities represent the current bottleneck to global benefit from genomics technologies.
The entire TWiV team assembles to discuss resurgence of COVID-19 in Manaus, Brazil, discovery of SARS-CoV-2 related viruses in bats in Southeast Asia and increased Ct values after administration of mRNA vaccine.
Webinars
Next generation sequencing (NGS) to identify the etiology of infectious disease has the potential to assist physicians in provided faster, pathogen-targeted antimicrobial therapy. ASM hosted a symposium on clinical metagenomics for infectious disease at World Microbe Forum 2021.
Network with Experts
The ASM Conference on Rapid Applied Microbial Next-Generation Sequencing and Bioinformatic Pipelines taking place October 2022 in Baltimore, Md. will feature leading experts on topics including sequencing in clinical and public health microbiology, bioinformatic tools, data integration and more.